NA

Naturalendo Tech Co., Ltd

Biotech R&D of natural ingredients for health and wellness solutions.

168330 | KO

Overview

Corporate Details

ISIN(s):
KR7168330009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 255 번길 58, 에이동 301호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Naturalendo Tech Co., Ltd. is a biotechnology company specializing in biosciences, herbs, and endocrinology. The company engages in the research, development, manufacturing, and sale of hormone biotechnology products, biological agents, and food additives. It focuses on developing health and beauty solutions derived from natural ingredients. The company's core activities revolve around the R&D and commercialization of new functional materials for the health and wellness sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-05-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.1 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 83.1 KB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.4 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.9 KB
2025-03-31 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.6 KB
2025-03-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.4 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.4 KB
2025-03-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.9 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.8 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB

Automate Your Workflow. Get a real-time feed of all Naturalendo Tech Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Naturalendo Tech Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Naturalendo Tech Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America
PRPO
PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210

Talk to a Data Expert

Have a question? We'll get back to you promptly.